Antihypertensive agents need to be tailored in accordance with underlying disease profile in hemodialysis patients, and no specific class of antihypertensive drug has proven to be more beneficial than others [9].
Randomized controlled clinical trials are needed to determine the most advantageous antihypertensive agent(s) to use in ESRD patients on chronic hemodialysis. Among all classes, CCBs are the most commonly prescribed antihypertensive agents [6] and offer the advantage of not being cleared during hemodialysis